[{"id":"415c095a-fdbb-4c01-9393-539ef53dc7d9","acronym":"SuRage-EB","url":"https://clinicaltrials.gov/study/NCT07092410","created_at":"2025-08-02T14:07:29.999Z","updated_at":"2025-08-02T14:07:29.999Z","phase":"Phase 4","brief_title":"Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib","source_id_and_acronym":"NCT07092410 - SuRage-EB","lead_sponsor":"SRH Wald-Klinikum Gera GmbH","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 101","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 08/01/2030","primary_completion_date":" 08/01/2030","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-07-29"},{"id":"1b1049ad-72e3-482d-a433-13cd63e6b89e","acronym":"UK-EnBiRiM","url":"https://clinicaltrials.gov/study/NCT07022457","created_at":"2025-06-21T13:21:55.578Z","updated_at":"2025-06-21T13:21:55.578Z","phase":"","brief_title":"UK ENcorafenib and BInimetinib Real-world Study in Melanoma","source_id_and_acronym":"NCT07022457 - UK-EnBiRiM","lead_sponsor":"Vitaccess Ltd","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/23/2025","start_date":" 06/23/2025","primary_txt":" Primary completion: 12/06/2027","primary_completion_date":" 12/06/2027","study_txt":" Completion: 12/06/2027","study_completion_date":" 12/06/2027","last_update_posted":"2025-06-15"},{"id":"9477387b-6d4d-44dc-94ca-1342835e5367","acronym":"BREAKWATER","url":"https://clinicaltrials.gov/study/NCT04607421","created_at":"2021-01-19T20:31:44.383Z","updated_at":"2025-02-25T13:53:29.320Z","phase":"Phase 3","brief_title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04607421 - BREAKWATER","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Zirabev (bevacizumab-bvzr) • Khapzory (levoleucovorin) • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 823","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 01/06/2025","primary_completion_date":" 01/06/2025","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-20"},{"id":"0e6f9786-f03c-47e3-82a4-50892d86b673","acronym":"","url":"https://clinicaltrials.gov/study/NCT06102902","created_at":"2023-10-26T15:14:21.567Z","updated_at":"2025-02-25T14:10:15.325Z","phase":"Phase 1","brief_title":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","source_id_and_acronym":"NCT06102902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/05/2024","start_date":" 06/05/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-17"},{"id":"37a71962-26f2-4826-b060-0159d0866f3c","acronym":"ECLYPse","url":"https://clinicaltrials.gov/study/NCT06640166","created_at":"2025-02-25T15:22:11.847Z","updated_at":"2025-02-25T15:22:11.847Z","phase":"Phase 2","brief_title":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","source_id_and_acronym":"NCT06640166 - ECLYPse","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/03/2024","start_date":" 06/03/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-12"},{"id":"59fe4335-1fcc-4358-b0b0-f40604168b4d","acronym":"HERKULES-3","url":"https://clinicaltrials.gov/study/NCT05039177","created_at":"2021-09-09T13:53:09.950Z","updated_at":"2025-02-25T15:19:15.517Z","phase":"Phase 1/2","brief_title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","source_id_and_acronym":"NCT05039177 - HERKULES-3","lead_sponsor":"Erasca, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-11"},{"id":"d94d46f3-da9f-4f88-b768-58de57db95e8","acronym":"C4901001","url":"https://clinicaltrials.gov/study/NCT05538130","created_at":"2022-09-13T11:56:07.923Z","updated_at":"2025-02-25T16:39:17.632Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors","source_id_and_acronym":"NCT05538130 - C4901001","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • claturafenib (PF-07799933)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 07/03/2029","study_completion_date":" 07/03/2029","last_update_posted":"2025-02-06"},{"id":"152d28df-5166-4844-8189-63865407b89e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05954546","created_at":"2023-07-20T23:10:56.186Z","updated_at":"2025-02-25T16:46:55.104Z","phase":"","brief_title":"A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings","source_id_and_acronym":"NCT05954546","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 07/21/2023","start_date":" 07/21/2023","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-05"},{"id":"d0abf381-bbfa-4b21-bbe7-740e5caad62b","acronym":"BEAVER","url":"https://clinicaltrials.gov/study/NCT03839342","created_at":"2021-01-18T18:57:15.711Z","updated_at":"2025-02-25T16:59:56.947Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations","source_id_and_acronym":"NCT03839342 - BEAVER","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRAF • KIAA1549","pipe":" | ","alterations":" BRAF mutation • BRAF V600K • BRAF fusion","tags":["BRAF • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600K • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"fbc97175-6cf6-4bb7-91ab-e5923255e6ef","acronym":"ZN-c3-016","url":"https://clinicaltrials.gov/study/NCT05743036","created_at":"2023-02-24T16:01:19.641Z","updated_at":"2025-02-25T17:02:25.578Z","phase":"Phase 1","brief_title":"ZN-c3 in Adult Participants With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05743036 - ZN-c3-016","lead_sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • azenosertib (ZN-c3)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 09/25/2026","study_completion_date":" 09/25/2026","last_update_posted":"2025-02-03"},{"id":"5b5025e1-918a-44f3-b1e4-127e110ec295","acronym":"","url":"https://clinicaltrials.gov/study/NCT05026983","created_at":"2021-08-30T21:53:02.254Z","updated_at":"2025-02-25T17:30:53.797Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases","source_id_and_acronym":"NCT05026983","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/27/2021","start_date":" 12/27/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-01-30"},{"id":"c140a8b8-ac68-4df9-988d-ebe6e54e87b6","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT06194929","created_at":"2024-01-08T19:20:11.355Z","updated_at":"2025-02-25T17:32:44.459Z","phase":"Phase 1/2","brief_title":"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma","source_id_and_acronym":"NCT06194929 - DETERMINE","lead_sponsor":"University of Utah","biomarkers":" NF1 • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation","tags":["NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/15/2028","primary_completion_date":" 01/15/2028","study_txt":" Completion: 01/15/2030","study_completion_date":" 01/15/2030","last_update_posted":"2025-01-30"},{"id":"c022581a-a340-436e-b4e7-18bfc5a946d3","acronym":"BRICKET","url":"https://clinicaltrials.gov/study/NCT06578559","created_at":"2025-02-25T16:02:55.886Z","updated_at":"2025-02-25T16:02:55.886Z","phase":"Phase 2","brief_title":"Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","source_id_and_acronym":"NCT06578559 - BRICKET","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 07/23/2024","start_date":" 07/23/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-01-23"},{"id":"ad4f690b-b51c-4f70-aa01-5da5b0887bb4","acronym":"CEBBRA","url":"https://clinicaltrials.gov/study/NCT06207656","created_at":"2024-01-17T16:18:48.040Z","updated_at":"2025-02-25T16:11:23.465Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer","source_id_and_acronym":"NCT06207656 - CEBBRA","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-10-21"},{"id":"a0cf279a-8d5c-46c3-9bca-6f57de2820c1","acronym":"NAUTICALCRC","url":"https://clinicaltrials.gov/study/NCT05004350","created_at":"2021-08-13T12:53:27.664Z","updated_at":"2025-02-25T16:16:36.860Z","phase":"Phase 2","brief_title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT05004350 - NAUTICALCRC","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type","tags":["BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/19/2023","primary_completion_date":" 12/19/2023","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-06-18"},{"id":"51654522-b1f1-419a-bdd1-387537311c21","acronym":"NCI-2022-02494","url":"https://clinicaltrials.gov/study/NCT05308446","created_at":"2022-04-04T14:52:50.907Z","updated_at":"2024-07-02T16:34:37.234Z","phase":"Phase 2","brief_title":"Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation","source_id_and_acronym":"NCT05308446 - NCI-2022-02494","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-06-07"},{"id":"2b720bdb-c868-4015-be63-be0574eeacf1","acronym":"PORTSIDE","url":"https://clinicaltrials.gov/study/NCT05926960","created_at":"2023-07-03T17:09:32.633Z","updated_at":"2024-07-02T16:34:59.560Z","phase":"Phase 2","brief_title":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","source_id_and_acronym":"NCT05926960 - PORTSIDE","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 05/23/2025","primary_completion_date":" 05/23/2025","study_txt":" Completion: 05/23/2027","study_completion_date":" 05/23/2027","last_update_posted":"2024-06-03"},{"id":"db82afaa-1da0-4791-94e2-92a3b0bc6788","acronym":"BECOME-MB","url":"https://clinicaltrials.gov/study/NCT04074096","created_at":"2021-01-18T19:57:18.686Z","updated_at":"2025-02-25T16:09:27.668Z","phase":"Phase 2","brief_title":"Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis","source_id_and_acronym":"NCT04074096 - BECOME-MB","lead_sponsor":"UNICANCER","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/05/2022","start_date":" 09/05/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2029","study_completion_date":" 04/15/2029","last_update_posted":"2024-06-03"},{"id":"ddcdaa98-710f-4836-a6b4-89e5e80022ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05957367","created_at":"2023-07-24T15:08:40.775Z","updated_at":"2024-07-02T16:34:59.920Z","phase":"Phase 1/2","brief_title":"A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies","source_id_and_acronym":"NCT05957367","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" BRAF • KIT • PDGFRA","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation","tags":["BRAF • KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • Qinlock (ripretinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-31"},{"id":"a4fa2c9b-d0d8-45aa-8666-8374568e8a92","acronym":"EBIN","url":"https://clinicaltrials.gov/study/NCT03235245","created_at":"2021-01-18T15:59:13.644Z","updated_at":"2024-07-02T16:35:00.361Z","phase":"Phase 2","brief_title":"Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","source_id_and_acronym":"NCT03235245 - EBIN","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 10/24/2023","primary_completion_date":" 10/24/2023","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-29"},{"id":"7f2b6ae3-35ab-4144-9fdd-b8dfede43457","acronym":"STARBOARD","url":"https://clinicaltrials.gov/study/NCT04657991","created_at":"2021-01-19T20:41:58.558Z","updated_at":"2024-07-02T16:35:03.047Z","phase":"Phase 3","brief_title":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","source_id_and_acronym":"NCT04657991 - STARBOARD","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 189","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-17"},{"id":"5bd6f499-beee-48f1-bd22-aa655569a28c","acronym":"SEAMARK","url":"https://clinicaltrials.gov/study/NCT05217446","created_at":"2022-02-05T18:28:13.127Z","updated_at":"2024-07-02T16:35:06.846Z","phase":"Phase 2","brief_title":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05217446 - SEAMARK","lead_sponsor":"Pfizer","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 07/11/2022","start_date":" 07/11/2022","primary_txt":" Primary completion: 03/28/2026","primary_completion_date":" 03/28/2026","study_txt":" Completion: 03/28/2027","study_completion_date":" 03/28/2027","last_update_posted":"2024-04-30"},{"id":"8d11e7de-5fd7-49f6-b0e9-31e7346e7fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04800822","created_at":"2021-03-16T14:52:26.431Z","updated_at":"2024-07-02T16:35:06.982Z","phase":"Phase 1","brief_title":"PF-07284892 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04800822","lead_sponsor":"Pfizer","biomarkers":" ALK • ROS1 • NF1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive","tags":["ALK • ROS1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/18/2024","primary_completion_date":" 06/18/2024","study_txt":" Completion: 11/29/2025","study_completion_date":" 11/29/2025","last_update_posted":"2024-04-30"},{"id":"fba96961-c2b5-441c-84a0-51876bc0c2d2","acronym":"COLUMBUS","url":"https://clinicaltrials.gov/study/NCT01909453","created_at":"2021-01-17T17:33:15.479Z","updated_at":"2024-07-02T16:35:07.254Z","phase":"Phase 3","brief_title":"Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma","source_id_and_acronym":"NCT01909453 - COLUMBUS","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 921","initiation":"Initiation: 09/16/2013","start_date":" 09/16/2013","primary_txt":" Primary completion: 11/09/2016","primary_completion_date":" 11/09/2016","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-04-26"}]